A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

NCT00349193 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: laquinimod 0.3
DRUG: laquinimod 0.6
OTHER: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.